FDA Gives Accelerated Approval to New ALS Treatment
Tofersen, an injection treatment for a rare form of ALS, has been approved under the accelerated approval pathway.
FDA Gives Accelerated Approval to New ALS Treatment Read More »
News
Dr. Weisman participates in FDA Advisory Committee
The committee convened to discuss tofersen, an experimental injection for treatment of ALS.
Dr. Weisman participates in FDA Advisory Committee Read More »
ANA administers first lecanemab infusion in PA
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
ANA administers first lecanemab infusion in PA Read More »
Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.
Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab Read More »
Lecanemab Reduces Cognitive Decline in Alzheimer’s
We hope to serve our community with infusions to help this unmet medical need while continuing to work on the next generation of Alzheimer treatments.
Lecanemab Reduces Cognitive Decline in Alzheimer’s Read More »
Dr. Weisman Quoted in NY Times Article on Aducanumab
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
Dr. Weisman Quoted in NY Times Article on Aducanumab Read More »
Aducanumab: Neither Far Nor Deep
While we might not have clear progress, we do have an advance.
Aducanumab: Neither Far Nor Deep Read More »
Aducanumab Update
While various opinions are circulating, and the benefits of this drug are unclear, ANA will continue to monitor the situation and provide updates as information becomes available.
Alzheimer’s Disease: Mystery No More
It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.
Alzheimer’s Disease: Mystery No More Read More »
Trailblazer clinical trial featured in New York Times
In the narrow window in which patients are aware of their disease, they have sought help in clinical trials. But enrolling enough participants to make these trials count is not easy.
Trailblazer clinical trial featured in New York Times Read More »
